Table 2 IHC expression of EGFR mutation antibodies in human NSCLC cell lines and in NSCLC tumor tissues
From: Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
EGFR mutation status | EGFR (D38B1) Ab (+) | EGFR E746-A750 deletion-specific (6B6) Ab (+) | EGFR L858R mutant-specific (43B2) Ab (+) |
|---|---|---|---|
H460 and A549 (WT) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) |
H1650 and PC9 (DEL 19) | 2/2 (100%) | 2/2 (100%) | 0/2 (0%) |
H1975 (L858R + T790M) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
Tumor Tissue (WT; N = 22) | 8/22 (36%) | 0/22 (0%) | 0/22(0%) |
Tumor Tissue (DEL 19;N = 29) | 28/29 (97%) | 20/29 (69%) | 0/29 (0%) |
Tumor Tissue (MUT 21;N = 27) | 26/27 (96%) | 0/27 (0%) | 25/27 (93%) |